O turismo e o desenvolvimento regional na fronteira Brasil-Paraguai

In recent years, on the Brazil-Paraguay border, the twin towns Porto Murtinho and Carmelo Peralta have received considerable attention from the authorities of both countries. The pair of towns will gain an international bridge, financed by ITAIPU Binational, which will join the Bioceanic Corridor of the Route of Latin American Integration (Rota de Integração Latino-Americana [RILA]). Designed to boost the export of commodities, linking the Port of Santos to ports in northern Chile, the RILA will also constitute a major infrastructure improvement aimed at developing tourism in that cross-border region. Thus, this article proposes, by means of a qualitative research study, based on bibliographic analysis, an approach to the possible impacts caused by the new transport infrastructure on the tourist potential of Porto Murtinho and Carmelo Peralta.En los últimos años, en la frontera Brasil-Paraguay, las ciudades gemelas Porto Murtinho y Carmelo Peralta han recibido una atención considerable por parte de las autoridades de ambos países. Este par de ciudades ganará un puente internacional, financiado por ITAIPU Binacional, que se unirá al Corredor Bioceánico de la Ruta de Integración Latinoamericana (RILA). Diseñada para impulsar la exportación de commodities, conectando el Puerto de Santos con los puertos del norte de Chile, la RILA también establecerá una importante infraestructura para el desarrollo del turismo en esa región transfronteriza. Así, este artículo propone, por medio de un estudio de investigación cualitativo, basado en análisis bibliográfico, un acercamiento a los posibles impactos causados ​​por la nueva infraestructura de transporte en el potencial turístico de Porto Murtinho y Carmelo Peralta.Ces dernières années, à la frontière Brésil-Paraguay, les villes jumelles Porto Murtinho et Carmelo Peralta ont reçu une attention considérable de la part des autorités des deux pays. Cette paire de villes gagnera un pont international, financé par ITAIPU Binational, qui rejoindra le Corridor Bioocéanique de la Route d’Intégration Latino-Américaine (RILA). Conçu pour stimuler l’exportation de commodities, reliant le Port de Santos aux ports du nord du Chili, le RILA établira également une infrastructure importante pour le développement du tourisme dans cette région transfrontalière. Ainsi, cet article propose, à travers une étude de recherche qualitative, basée sur une analyse bibliographique, une approche des impacts possibles causés par la nouvelle infrastructure de transport sur le potentiel touristique de Porto Murtinho et Carmelo Peralta.Nos últimos anos, na fronteira Brasil-Paraguai, as cidades gêmeas Porto Murtinho e Carmelo Peralta têm recebido especial atenção por parte das autoridades dos dois países. O par de cidades será contemplado com uma ponte internacional, financiada pela Itaipu Binacional, que deverá compor o Corredor Bioceânico da Rota de Integração Latino-Americana (RILA). Projetada para potencializar a exportação de commodities, unindo o Porto de Santos aos portos do norte do Chile, a RILA também irá configurar importante infraestrutura para o desenvolvimento do turismo naquela região transfronteiriça. Nesse sentido, este artigo traz, a partir de uma pesquisa qualitativa, pautada em análise bibliográfica, uma abordagem dos possíveis impactos ocasionados pela nova infraestrutura de transportes no potencial turístico de Porto Murtinho e Carmelo Peralta

ZICOSUL E A PARADIPLOMACIA NAS FRONTEIRAS DA AMÉRICA DO SUL

Criada em 1997, a ZICOSUL (Zona de Integração do Centro-Oeste da América do Sul) constitui uma iniciativa em prol do desenvolvimento regional do subcontinente sul-americano. Composta por governos regionais dos países da região, no Brasil cinco estados fazem parte da Organização. Passadas duas décadas do início da iniciativa a mesma é muito pouco conhecida e difundida na mídia. Nesse sentido, o presente artigo tem o objetivo de analisar a ZICOSUL no âmbito da paradiplomacia em zonas de fronteira do Centro Oeste da América do Sul, área chave para a integração regional do subcontinente. O artigo traz ainda uma análise da paradiplomacia desenvolvida no estado de Mato Grosso do Sul. Trata-se de uma pesquisa qualitativa, pautada em análise bibliográfica e documental, sob a ótica das Relações Internacionais e do Desenvolvimento Regional, enriquecida com cartografia temática elaborada pelos autores

ATLANTIC BIRDS: a data set of bird species from the Brazilian Atlantic Forest

South America holds 30% of the world's avifauna, with the Atlantic Forest representing one of the richest regions of the Neotropics. Here we have compiled a data set on Brazilian Atlantic Forest bird occurrence (150,423) and abundance samples (N = 832 bird species; 33,119 bird individuals) using multiple methods, including qualitative surveys, mist nets, point counts, and line transects). We used four main sources of data: museum collections, on-line databases, literature sources, and unpublished reports. The data set comprises 4,122 localities and data from 1815 to 2017. Most studies were conducted in the Florestas de Interior (1,510 localities) and Serra do Mar (1,280 localities) biogeographic sub-regions. Considering the three main quantitative methods (mist net, point count, and line transect), we compiled abundance data for 745 species in 576 communities. In the data set, the most frequent species were Basileuterus culicivorus, Cyclaris gujanensis, and Conophaga lineata. There were 71 singletons, such as Lipaugus conditus and Calyptura cristata. We suggest that this small number of records reinforces the critical situation of these taxa in the Atlantic Forest. The information provided in this data set can be used for macroecological studies and to foster conservation strategies in this biodiversity hotspot. No copyright restrictions are associated with the data set. Please cite this Data Paper if data are used in publications and teaching events. © 2017 by the Ecological Society of Americ

Photography-based taxonomy is inadequate, unnecessary, and potentially harmful for biological sciences

The question whether taxonomic descriptions naming new animal species without type specimen(s) deposited in collections should be accepted for publication by scientific journals and allowed by the Code has already been discussed in Zootaxa (Dubois & Nemésio 2007; Donegan 2008, 2009; Nemésio 2009a–b; Dubois 2009; Gentile & Snell 2009; Minelli 2009; Cianferoni & Bartolozzi 2016; Amorim et al. 2016). This question was again raised in a letter supported by 35 signatories published in the journal Nature (Pape et al. 2016) on 15 September 2016. On 25 September 2016, the following rebuttal (strictly limited to 300 words as per the editorial rules of Nature) was submitted to Nature, which on 18 October 2016 refused to publish it. As we think this problem is a very important one for zoological taxonomy, this text is published here exactly as submitted to Nature, followed by the list of the 493 taxonomists and collection-based researchers who signed it in the short time span from 20 September to 6 October 2016

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants.

BACKGROUND: Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. METHODS: We used data from 1990 to 2019 on people aged 30-79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. FINDINGS: The number of people aged 30-79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306-359) million women and 317 (292-344) million men in 1990 to 626 (584-668) million women and 652 (604-698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55-62) of women and 49% (46-52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43-51) of women and 38% (35-41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20-27) for women and 18% (16-21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. INTERPRETATION: Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings. FUNDING: WHO

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

Background Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. Methods We used data from 1990 to 2019 on people aged 30-79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. Findings The number of people aged 30-79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306-359) million women and 317 (292-344) million men in 1990 to 626 (584-668) million women and 652 (604-698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55-62) of women and 49% (46-52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43-51) of women and 38% (35-41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20-27) for women and 18% (16-21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. Interpretation Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings. Copyright (C) 2021 World Health Organization; licensee Elsevier

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

Background Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. Methods We used data from 1990 to 2019 on people aged 30–79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. Findings The number of people aged 30–79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306–359) million women and 317 (292–344) million men in 1990 to 626 (584–668) million women and 652 (604–698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55–62) of women and 49% (46–52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43–51) of women and 38% (35–41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20–27) for women and 18% (16–21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. Interpretation Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

Background Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. Methods We used data from 1990 to 2019 on people aged 30–79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. Findings The number of people aged 30–79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306–359) million women and 317 (292–344) million men in 1990 to 626 (584–668) million women and 652 (604–698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55–62) of women and 49% (46–52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43–51) of women and 38% (35–41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20–27) for women and 18% (16–21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. Interpretation Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings

ESTUDO COMPARATIVO TÉCNICO, ECONÔMICO, E AMBIENTAL DAS FONTES DE ENERGIAS RENOVÁVEIS, E DISTRIBUIÇÃO ELÉTRICA

<p>Considerando o aumento da demanda por energia e a necessidade de diversificação das matrizes energéticas em todo o mundo, se faz necessário analisar os aspectos técnicos, os impactos ambientais e a viabilidade econômica e energética das tecnologias disponíveis para geração de energia elétrica. Este estudo aborda a importância da eficiência energética, os desafios na implementação de sistemas energéticos baseados em fontes de energias renováveis e o papel crucial desses recursos energéticos, como uma alternativa financeiramente viável e ecologicamente correta. São abordados também os principais conceitos envolvidos no que se refere à distribuição elétrica on-grid e off-grid, bem como, descrever os desafios que envolvem a sua implementação.</p><p>Portanto, este artigo trata-se de uma revisão bibliográfica, cujos dados foram coletados mediante pesquisa de produções científicas e de bases de dados sobre a utilização de fontes de energias renováveis como meio de geração de energia elétrica.</p><p>Nesse sentido, foram comparados e analisados os aspectos econômicos, ambientais e energéticos das principais fontes de energias renováveis presentes na matriz elétrica brasileira, sendo elas: energia eólica, energia fotovoltaica, energia hidrelétrica, energia biomassa e energia biogás. </p><p>Os resultados obtidos da análise comparativa demonstram que, dentre as fontes de energia renováveis, objetos de estudo neste artigo, a energia eólica, é a que possui o menor índice de custo nivelado de eletricidade (LCOE) e o terceiro maior retorno sobre o investimento em energia (EROI). Sendo assim, é a fonte de energia renovável que apresenta os melhores resultados gerais.</p&gt